EP0686150B1 - Verfahren zur Herstellung von C-Nukleosiden und C-Nukleosid-Analoga, neue C-Nukleoside und C-Nukleosid-Analoga, sowie ihre Verwendung - Google Patents
Verfahren zur Herstellung von C-Nukleosiden und C-Nukleosid-Analoga, neue C-Nukleoside und C-Nukleosid-Analoga, sowie ihre Verwendung Download PDFInfo
- Publication number
- EP0686150B1 EP0686150B1 EP94910321A EP94910321A EP0686150B1 EP 0686150 B1 EP0686150 B1 EP 0686150B1 EP 94910321 A EP94910321 A EP 94910321A EP 94910321 A EP94910321 A EP 94910321A EP 0686150 B1 EP0686150 B1 EP 0686150B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hal
- alkyl
- methyl
- didesoxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002777 nucleoside Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 6
- 229940127073 nucleoside analogue Drugs 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000003835 nucleoside group Chemical group 0.000 claims abstract description 5
- 102000053642 Catalytic RNA Human genes 0.000 claims description 11
- 108090000994 Catalytic RNA Proteins 0.000 claims description 11
- 108091092562 ribozyme Proteins 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- QWIDYOLZFAQBOB-UHFFFAOYSA-N 2-methyl-1h-pyrimidin-6-one Chemical compound CC1=NC=CC(=O)N1 QWIDYOLZFAQBOB-UHFFFAOYSA-N 0.000 claims description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 6
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 6
- GKVDLTTVBNOGNJ-UHFFFAOYSA-N 2-methylpyrimidin-4-amine Chemical compound CC1=NC=CC(N)=N1 GKVDLTTVBNOGNJ-UHFFFAOYSA-N 0.000 claims description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- -1 bromovinyl Chemical group 0.000 claims description 4
- 150000003230 pyrimidines Chemical class 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 1
- GNCLPNMQEGMNTG-UHFFFAOYSA-N 2-methylpyridin-4-amine Chemical compound CC1=CC(N)=CC=N1 GNCLPNMQEGMNTG-UHFFFAOYSA-N 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000012830 cancer therapeutic Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 1
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 230000003327 cancerostatic effect Effects 0.000 abstract description 3
- 230000001790 virustatic effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- UJQBOUAGWGVOTI-XSSZXYGBSA-N 1-[(2r,4s,5r)-4-azido-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@](O)(N=[N+]=[N-])C1 UJQBOUAGWGVOTI-XSSZXYGBSA-N 0.000 description 2
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003580 thiophosphoric acid esters Chemical class 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- KOQIJEFMVNFVFW-UUOKUNOPSA-N (2R,3R,4S,5R)-2-(6-amino-2-methylpyrimidin-4-yl)-5-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound O[C@]1([C@H](O)[C@H](O)[C@H](O1)CO)C1=CC(=NC(=N1)C)N KOQIJEFMVNFVFW-UUOKUNOPSA-N 0.000 description 1
- FCPPMEHRCOVNTC-FWKUWYBHSA-N (2r,3s,4r)-2-(hydroxymethyl)-5-(pyrimidin-4-ylmethyl)oxolane-3,4-diol Chemical class O[C@@H]1[C@H](O)[C@@H](CO)OC1CC1=CC=NC=N1 FCPPMEHRCOVNTC-FWKUWYBHSA-N 0.000 description 1
- MQFJMMRPGXSEBY-UHFFFAOYSA-N (6-methylpyrimidin-4-yl)oxy-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC1=CC(C)=NC=N1 MQFJMMRPGXSEBY-UHFFFAOYSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- YKUFMYSNUQLIQS-UHFFFAOYSA-N 2-amino-5-methyl-1h-pyrimidin-6-one Chemical compound CC1=CNC(N)=NC1=O YKUFMYSNUQLIQS-UHFFFAOYSA-N 0.000 description 1
- YUMWPLUOCVEJOI-QYYRPYCUSA-N 2-amino-5-methyl-4-[(2R,3R,4S,5R)-2,3,4-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-pyrimidin-6-one Chemical compound O[C@]1([C@H](O)[C@H](O)[C@H](O1)CO)C1=C(C(=NC(=N1)N)O)C YUMWPLUOCVEJOI-QYYRPYCUSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 0 CCC1C(*S)C*C1 Chemical compound CCC1C(*S)C*C1 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LTIIRCGGLJKEDH-UHFFFAOYSA-N [4-methyl-6-tri(propan-2-yl)silyloxypyrimidin-2-yl]oxy-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)OC1=CC(C)=NC(O[Si](C(C)C)(C(C)C)C(C)C)=N1 LTIIRCGGLJKEDH-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- ZLRAAUUPULJGTL-UHFFFAOYSA-N diaminophosphinous acid Chemical compound NP(N)O ZLRAAUUPULJGTL-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000000548 ribosyl group Chemical class C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- OLRJXMHANKMLTD-UHFFFAOYSA-N silyl Chemical compound [SiH3] OLRJXMHANKMLTD-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- WAQFVHDESWWOPB-UHFFFAOYSA-N trimethyl(trimethylsilyloxyperoxy)silane Chemical compound C[Si](C)(C)OOO[Si](C)(C)C WAQFVHDESWWOPB-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- the invention relates to a method for producing C-nucleosides and C-nucleoside analogs, new C-nucleosides and C-nucleoside analogs and their use.
- the new C-nucleosides and C-nucleoside analogues have not yet been synthesized.
- 6- (D-Ribofuranosylmethyl) pyrimidines are known from J. Org. Chem. 43, 2925 (1978), 47, 5115 (1982), 51, 1058 (1986), Liebigs Annalen 6, 957 (1986), J. Chem. Soc. Perkin I 201 (1983).
- nucleosides For the treatment of viral and cancer diseases is one Series of nucleosides have been synthesized and tested. Several of which are used in medical practice today, e.g. Acyclovir (Schaeffer et al, Nature 1978, 272, 583-85) and 3'-azidothymidine (Broder et al, Proc. Natl. Acad. Sci., USA, 1985, 82, 7096). Others are used as therapeutic agents shortly before, among others for 5- (2-bromovinyl) -2'-deoxyuridine and 3'-fluorothymidine.
- the invention aims to be therapeutic, in particular Virostatic and cancerostatic compounds are available to ask which one with the known substances comparable effectiveness and high stability. she are said to be potential therapeutic agents with low stress for be suitable for the patient.
- Another object of the invention consists of building blocks for novel oligonucleotides to provide.
- the compounds I are virostatic and / or cancerostatic. Their effectiveness has been tested on bone marrow stem cells. The compounds show an inhibition in the bone marrow stem cell proliferation test that is comparable to the known substances and in some cases even higher. It is, for example, 6- ( ⁇ -D-2 ', 3'-didehydro-2', 3'-dideoxyribofuranos-1-yl) methyl-4-aminopyrimidine below 10 -4 molar.
- Synthetic oligonucleotides are understood to mean RNA and DNA oligonucleotides, including above all ribozymes (also ribozymes from DNA and RNA building blocks) and antisense oligonucleotides.
- the compounds mentioned in claim 5 are preferably used for this.
- Such compounds are prepared according to a known pattern, some typical routes are described below using the example of thymidine.
- thymidine is first tritylated to the 5'-dimethoxy-trityl derivative, followed by reaction via cyanoethyl (diisopropyl) phosphorodiamidite.
- the resulting 5'-di-methoxy-trityl-3'-cyanoethyl (diisopropyl) phosphamidite is then reacted further in a manner known per se in the oligonucleotide synthesizer.
- RNA oligonucleotides after tritylation protection of the 2'-OH group z. B. done by the silyl radical.
- ribozymes and antisense oligonucleotides are constructed in the same way.
- Compounds which are particularly suitable for the construction of the ribozyme are 6- ( ⁇ -D-ribofuranos-1-yl) methyl-4-aminopyrimidine and 6- ( ⁇ -D-ribofuranos-1-yl) methyl-2-amino-4-hydroxy-pyrimidine and their derivatives substituted in the 2'-position by F, NH 2 , H or ara-OH. These compounds can be used as phosphate esters, thiophosphate esters or as phosphonates.
- These compounds can also be used as phosphate esters, thiophosphate esters or as phosphonates.
- the novel antisense oligonucleotides produced show an increased specific activity and an increased ability to bind to the desired support, which results in improved application possibilities.
- the invention further relates to a process for the preparation of the compounds I by reacting an esterified or etherified 1-halogenose of the general formula II (see drawing sheet 3/4) with C-metalated pyrimidines or their mono-, di- or trimethylsilyloxy ether or - alkyl ethers of the general formula III, the NH 2 groups which may be present in the 2- and / or 4-position are protected, preferably by a dimethyl aminomethylene group (see drawing sheet 4/4), at temperatures from -70 ° C. to +100 ° C, preferably at -70 ° C to -50 ° C.
- the detailed procedure is as follows.
- the halogenose II is dissolved in an inert solvent such as alkanes, ethers or aromatics, cooled to -70 ° C. to 0 ° C. and the C-metalated pyrimidine III is added dropwise.
- These metal compounds III are prepared by reacting the corresponding persilylated or other etherified pyrimidine derivatives with organometallic compounds, for example butyllithium or sodium amide.
- the reaction mixture is then preferably brought to room temperature and, if necessary, heated briefly to complete the reaction. After completion of the reaction, recognizable by the precipitated metal salt, the desired product is obtained after the usual chemical operations.
- reaction according to the invention preferably when etherified halogenoses are used, is that the halogenose II is placed in an inert solvent and the C-metalated pyrimidine III is added with constant stirring. Absolute freedom from water is essential for the success according to the invention.
- reaction solution If the reaction solution is neutral, it is evaporated in a rotary evaporator and deacylated with sodium methylate and separated on silica gel (Merck 60) with chloroform-methanol (9/1) into ⁇ , ⁇ anomers.
- F: 125 °, M: 242.2 ⁇ C 10 H 14 N 2 O 5 according to MS Varian CH 7 300 MHz NMR: H ' 6.4146 ppm ⁇ ⁇
- the ⁇ -anomer can be converted into cytosine, Isocytosine and others Derivatives are implemented that are the purine derivatives Adenine, inosine, xanthine, guanine and others correspond.
- the toluene solution is extracted with cold water, the organic phase is dried (MgSO 4 ), the solvent is evaporated and the residue is deacylated with 100 ml of 1 / 20m NaOCH 3 solution.
- the solution is then neutralized with Dowex H + ion exchanger, the glycoside and unreacted pyrimidine are subsequently detached from the ion exchanger and separated into ⁇ - and ⁇ -anomers via a silica gel column.
- Syrup, M 226.23 ⁇ C 10 H 14 N 2 O 4 mass peak CH 7 (Varian)
- Example 3 50 mg of the compound prepared in Example 3 are in 2 ml Hexamethyldisilazane and 1 drop of DMF slowly warmed until the Substance goes into solution. Excess hexamethyldisilazane removed in vacuo, and the residue is mixed with 2 ml liquefied ammonia and catalytic amounts of ammonium chloride heated in a bomb tube at 160 ° C overnight. After evaporating the Ammoniaks the residue is taken up in methanol and on Silica gel 60 (Merck) separated with chloroform / methanol 9/1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Die neuen C-Nukleoside und C-Nukleosidanaloga konnten bisher nicht synthetisiert werden.
Zum Aufbau von RNA-Oligonukleotiden muß nach der Tritylierung ein Schutz der 2'-OH-Gruppe z. B. durch den Silylrest erfolgen. Der Aufbau von Ribozymen und von Antisense-Oligonukleotiden erfolgt in prinzipiell gleicher Weise.
- durch Substitution der 2'-OH-Gruppe, z. B. durch F oder durch NH2,
- durch Ersatz der Phosphatreste durch Thiophosphate und
- durch Ersatz der Phosphatreste durch Phosphonate.
6-(β-D-2'-Desoxyribofuranos-1-yl)methyl-4-aminopyrimidin und
6-(β-D-2'-Desoxyribofuranos-l-yl)methyl-2-amino-4-hydroxypyrimidin und deren Ribose-Analoga.
Diese Verbindungen können ebenfalls als Phosphatester, Thiophosphatester oder als Phosphonate eingesetzt werden. Die hergestellten neuartigen Antisense-Oligonukleotide zeigen eine erhöhte spezifische Aktivität und eine erhöhte Bindungsfähigkeit am gewünschten Träger, wodurch sich verbesserte Anwendungsmöglichkeiten ergeben.
Das Verfahren läuft im einzelnen folgendermaßen ab.
Die Halogenose II wird in einem inerten Lösungsmittel wie Alkanen, Äthern oder Aromaten gelöst, auf -70°C bis 0°C abgekühlt und tropfenweise mit dem C-metallierten Pyrimidin III versetzt. Diese Metallverbindungen III werden durch Umsetzung der entsprechenden persilylierten oder anders verätherten Pyrimidin-Derivate mit metallorganischen Verbindungen z.B. Butyllithium oder Natriumamid, hergestellt. Anschließend wird das Reaktionsgemisch bevorzugt auf Raumtemperatur gebracht und gegebenenfalls zur Vervollständigung der Umsetzung kurz erwärmt. Nach Beendigung der Umsetzung, erkennbar an ausgefallenem Metallsalz, erhält man nach den üblichen chemischen Operationen das gewünschte Produkt.
Eine andere Variante der erfindungsgemäßen Umsetzung, bevorzugt beim Einsatz von verätherten Halogenosen,besteht darin, daß man die Halogenose II in einem inerten Lösungsmittel vorlegt und das C-metallierte Pyrimidin III unter ständigem Rühren zusetzt. Von wesentlicher Bedeutung für den erfindungsgemäßen Erfolg ist die absolute Wasserfreiheit.
F: 125°, M: 242,2 ≙ C10H14N2O5 laut MS Varian CH7
300 MHz NMR: H' = 6,4146 ppm ≙ β
Sirup, M= 226,23 ≙ C10H14N2O4 Massenpeak CH7 (Varian)
Die Chloroformlösung wird einrotiert, der Rückstand in Acetanhydrid erwärmt, bis der Pyrimidinring vollständig acyliert ist. Eine teilweise Detritylierung stört die nachfolgende Eliminierung nicht. Der nach erneutem Einrotieren erhaltene Rückstand wird in 5 ml DMF aufgenommen und mit 5 ml Ethyldiisopropylamin unter Rückfluß gekocht, bis die Ausgangsverbindung nicht mehr im Dünnschichtchromatogramm nachweisbar ist. Nach erneutem Einrotieren werden die Schutzgruppen in bekannter Weise entfernt und der verbliebene Rückstand an Kieselgel 60 (Merck) mit Chloroform/Methanol 9/1 getrennt.
Die Titelverbindung wird durch die für En-Verbindungen typische Bromentfärbung nachgewiesen.
Claims (20)
- Verfahren zur Herstellung von C-Nukleosiden und C-NukleosidAnaloga der allgemeinen Formel I wobei
- R1 =
- H, Hal, OH, SH, NH2, N3, CN,
- R2 =
- H, Hal, OH, SH, NH2, N3, CN, NH-NH2
- R3 =
- H, Hal, OH, NH2, N3, Alkyl, Aryl, NO, NO2 NH-NH2, NH-Aryl, NH-Alkyl, CH2-Hal, Vinyl, Bromvinyl,
- R4 =
- H, Hal, OH, Alkyl, -NH2, NH-Alkyl, NH-Aryl, CN
- R5 =
- H, Hal, OH, Alkyl, NH2, NH-Alkyl, NH-Aryl, CN, R4+R5 zusammen = O, S, N-Aryl, N-Alkyl, N-NH-Aryl, N-NH-Alkyl,
- R6 =
- und
- R7 =
- H, Hal, OH,
- R8 =
- H, Hal, OH,
- R9 =
- H, Hal, OH, N3
bedeuten,
dadurch gekennzeichnet, daß man eine veresterte oder verätherte 1-Halogenose der allgemeinen Formel II wobei R11 = H, O-Acyl, O-Alkyl, O-Aryl, O-Silyl,
mit C-metallierten Pyrimidinen bzw. ihren Mono- oder Bis-, Trimethylsilyloxyäthern oder -alkyläthern der allgemeinen Formel III, deren ggf. in 2- und/oder 4-Stellung vorhandene NH2-Gruppen geschützt sind, vorzugsweise durch eine Dimethyl-aminomethylengruppe, in der R1 bis R5 die o.g. Bedeutung hat und
Me = Li, Na ist,
bei Temperaturen von -70°C bis +100°C umsetzt, vorzugsweise bei -70°C bis -50°C, und nachfolgend gegebenenfalls mit in der Nukleosidchemie üblichen Operationen weiter umsetzt. - Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Halogenose II bei -70°C bis 0°C in einem inerten Lösungsmittel, vorzugsweise in Alkanen, Äthern oder Aromaten, gelöst und tropfenweise mit dem C-metallierten Pyrimidin III im gleichen Lösungsmittel versetzt wird, das Reaktionsgemisch nachfolgend auf Raumtemperatur gebracht und gegebenenfalls zur Vervollständigung der Umsetzung kurz erwärmt wird.
- Verfahren nach Anspruch 1 und 2, dadurch gekennzeichnet, daß man die entsprechenden persilylierten Pyrimidin-Derivate mit metallorganischen Verbindungen wie Butyllithium oder Natriumamid umsetzt und die gebildete Verbindung III im Reaktionsgemisch direkt mit der Halogenose II umsetzt.
- 6-Methylensubstituierte Nukleoside des4-Hydroxypyrimidins,4-Aminopyrimidins,2-Amino-4-hydroxypyrimidins und des2,4-Diaminopyrimidins2',3'-Didesoxy-ribose3'-Azido-2',3'-didesoxy-ribose3'-Fluor-2',3'-didesoxy-ribose2'-Fluor-ara-2',3'-didesoxy-ribose2',3'-Didehydro-2',3'-didesoxy-ribose.
- 6-(β-D-2',3'-Didesoxyribofuranos-1'-yl)methyl-4-hydroxypyrimidin.
- 6-(β-D-2',3'-Didesoxyribofuranos-1'-yl)methyl-4-aminopyrimidin.
- 6-(β-D-2',3'-Didehydro-2',3'-didesoxy-ribofuranos-1'-yl)methyl-4-hydroxypyrimidin.
- 6-(β-D-2',3'-Didehydro-2',3'-didesoxy-ribofuranos-1'-yl) methyl-4-aminopyrimidin.
- 6-(β-D-2',3'-Didesoxy-3'-fluor-ribofuranos-1'-yl)methyl-4-hydroxypyrimidin.
- 6-(β-D-2',3'-Didesoxy-3'-fluor-ribofuranos-1'-yl)methyl-4-aminopyrimidin.
- 6-(β-D-2',3'-Didesoxy-3'-azido-ribofuranos-1'-yl)methyl-4-hydroxypyrimidin.
- Pharmazeutische Zusammensetzung enthaltend Verbindungen I als Virostatikum.
- Pharmazeutische Zusammensetzung enthaltend Verbindungen I als Krebstherapeutikum.
- Verwendung der Verbindungen I als Bausteine für synthetische Oligonukleotide.
- Verwendung nach Anspruch 14 als Bausteine für synthetische RNA-Oligonukleotide.
- Verwendung nach Anspruch 14 als Bausteine für synthetische DNA-Nukleotide.
- Verwendung nach Anspruch 14 und 15 zur Synthese von neuartigen Ribozymen.
- Verwendung nach Anspruch 14-17 zur Synthese von Ribozymen aus DNA- und RNA-Bausteinen.
- Verwendung nach Anspruch 14 und 16 bis 18 zur Synthese von neuartigen DNA-Antisense-Oligonukleotiden.
- Verwendung nach Anspruch 14, 15, 17 und 18 zur Synthese von neuartigen RNA-Antisense-Oligonukleotiden.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4306859 | 1993-02-26 | ||
DE4306859 | 1993-02-26 | ||
DE4320570 | 1993-06-15 | ||
DE4320570A DE4320570C2 (de) | 1993-02-26 | 1993-06-15 | Verfahren zur Herstellung von C-Nukleosiden und C-Nukleosid-Analoga, neue C-Nukleoside und C-Nukleosid-Analoga sowie deren Verwendung |
PCT/DE1994/000205 WO1994019327A1 (de) | 1993-02-26 | 1994-02-24 | Nukleoside, ihre herstellung und ihre verwendung als therapeutikum und als baustein für synthetische oligonukleotide |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0686150A1 EP0686150A1 (de) | 1995-12-13 |
EP0686150B1 true EP0686150B1 (de) | 1998-05-20 |
Family
ID=25923662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94910321A Expired - Lifetime EP0686150B1 (de) | 1993-02-26 | 1994-02-24 | Verfahren zur Herstellung von C-Nukleosiden und C-Nukleosid-Analoga, neue C-Nukleoside und C-Nukleosid-Analoga, sowie ihre Verwendung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0686150B1 (de) |
AT (1) | ATE166347T1 (de) |
WO (1) | WO1994019327A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3911703B2 (ja) * | 1994-12-15 | 2007-05-09 | 日本新薬株式会社 | アンチセンス核酸同族体 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4532240A (en) * | 1982-09-09 | 1985-07-30 | Warner-Lambert Company | Diaminopyrimidines |
CA2479846C (en) * | 1989-05-15 | 2007-07-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Phosphonomethoxymethylpurine/pyrimidine derivatives |
-
1994
- 1994-02-24 WO PCT/DE1994/000205 patent/WO1994019327A1/de active IP Right Grant
- 1994-02-24 AT AT94910321T patent/ATE166347T1/de not_active IP Right Cessation
- 1994-02-24 EP EP94910321A patent/EP0686150B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE166347T1 (de) | 1998-06-15 |
EP0686150A1 (de) | 1995-12-13 |
WO1994019327A1 (de) | 1994-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5194599A (en) | Hydrogen phosphonodithioate compositions | |
DE69806919T2 (de) | Antivirale pyrimidin-nukleosid-analogen | |
DE3687397T2 (de) | 2-fluorarabinofuranosylpurinnukleoside. | |
DE69318836T2 (de) | 1,5-anhydrohexitolnukleosidanaloge und pharmazeutische verwendung davon | |
EP0254268B2 (de) | Fluorierte Nucleoside, ihre Herstellung und ihre pharmazeutische Verwendung gegen AIDS | |
EP0624161B1 (de) | 2'-desoxy-isoguanosine, isostere analoge und isoguanosinderivate sowie deren anwendung | |
DE60005501T2 (de) | 4'-c-ethynyl-pyrimidine nukleoside | |
DE3887273T2 (de) | 2',3'-Dideoxy-2'-fluornucleoside. | |
DE69715774T2 (de) | 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)-cytosine | |
DE69029733T2 (de) | Nukleosidderivate von 2-halo-9(2-oxy-2-fluoro-beta-d-arabinofuranosyl)adenin | |
DE3785343T2 (de) | Alpha-oligonukleotide. | |
WO2008125583A1 (de) | Ethinylierte heterodinucleosidphosphatanaloga, verfahren zu deren herstellung und deren verwendung | |
DE19509038A1 (de) | C-Nukleosid-Derivate und deren Verwendung in der Detektion von Nukleinsäuren | |
DE2228750A1 (de) | 4'-fluornucleoside, neue zwischenprodukte und verfahren zur herstellung derselben | |
EP0763047B1 (de) | Neues verfahren zur herstellung von nucleosiden | |
DE60204859T2 (de) | Verfahren zur Herstellung von 2'-Halo-beta-L-arabino-furanosylnucleosiden | |
WO1996032403A2 (de) | Neue cytosin- und cytidinderivate | |
EP0015584A2 (de) | Neue Nukleotide, Verfahren zu ihrer Herstellung und Arzneimittel | |
EP0686150B1 (de) | Verfahren zur Herstellung von C-Nukleosiden und C-Nukleosid-Analoga, neue C-Nukleoside und C-Nukleosid-Analoga, sowie ihre Verwendung | |
DE4320570C2 (de) | Verfahren zur Herstellung von C-Nukleosiden und C-Nukleosid-Analoga, neue C-Nukleoside und C-Nukleosid-Analoga sowie deren Verwendung | |
Thomas et al. | Synthesis and biologic activity of purine 2′-deoxy-2′-fluoro-ribonucleosides | |
EP2321330B1 (de) | Verfahren zur herstellung phosphatverbrückter nucleosid-konjugate | |
EP0611373B1 (de) | Oligo-2'-desoxynukleotide und ihre verwendung als arzneimittel mit antiviraler wirksamkeit | |
DE19618727C2 (de) | Herstellung alkylierter Nucleosid-3'-Phosphate | |
AU4234193A (en) | Synthesis of nucleotide monomers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950911 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DK ES FR GB IT LI NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19960919 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DK ES FR GB IT LI NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980520 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 19980520 Ref country code: GB Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980520 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980520 Ref country code: ES Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19980520 |
|
REF | Corresponds to: |
Ref document number: 166347 Country of ref document: AT Date of ref document: 19980615 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980820 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980820 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 19980820 |
|
EN | Fr: translation not filed | ||
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
GBV | Gb: ep patent (uk) treated as always having been void in accordance with gb section 77(7)/1977 [no translation filed] |
Effective date: 19980520 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990224 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990228 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990228 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19990228 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
BERE | Be: lapsed |
Owner name: MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN Effective date: 19990228 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |